• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 48
  • 47
  • 20
  • 15
  • 6
  • 6
  • 4
  • 3
  • 2
  • 1
  • 1
  • Tagged with
  • 176
  • 37
  • 37
  • 26
  • 25
  • 23
  • 23
  • 23
  • 22
  • 22
  • 21
  • 20
  • 19
  • 18
  • 16
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
121

Étude sur l'effet de l'activation du TLR4 des macrophages humains sur la réplication du VIH-1

Simard, Sébastien 11 April 2018 (has links)
Les Toll-Like Receptors (TLRs) jouent un rôle majeur dans la réponse immunitaire innée, en reconnaissant des motifs moléculaires précis retrouvés exclusivement chez différents pathogènes (lipopolysaccharides (LPS), peptidoglycane, flagelline, ...). Le LPS est reconnu pour favoriser la production de cytokines pro-inflammatoires (ex. IL-1, IL-8, et TNF-ot) par les monocytes/macrophages via l'induction du facteur de transcription NK-KB par le TLR4. D'autre part, le virus d'immunodéficience humaine de type I (VIH-1) possède deux sites de liaison pour NF-KB dans sa région promotrice. L'objectif de cette étude était de vérifier l'effet de la stimulation au LPS sur la réplication et la production du VIH-1 dans une lignée cellulaire macrophagique ainsi que dans les macrophages primaires humains. L'ensemble des résultats obtenus montre que le LPS augmente l'activation de la transcription dans la lignée THP89GFP, alors que le contraire est observé dans les macrophages primaires humains et ce même si l'activation de NF-KB et la production de TNF-a sont observées dans ces cellules suite à un traitement au LPS. Cette étude révèle que les conclusions faites à partir d'une lignée cellulaire bien établie ne peuvent directement être appliquées à une un modèle plus physiologique. Ainsi, la réponse aux ligands des TLR devrait être étudiée dans un système de culture cellulaire beaucoup plus proche de la situation in vivo. / Toll-Like Receptors (TLRs) play a major role in the innate immune response, by recognizing precise molecular patterns found exclusively on different pathogens (lipopolysaccharides/LPS, peptidoglycans, flagellin, etc.). LPS is known to induce the production of pro-inflammatory cytokines (e.g. IL-1, IL-8, and TNF-a) by monocytes/macrophages through TLR4-mediated induction of the transcription factor NFKB. Interestingly, HIV-1 carries two consensus NF-KB binding sequences within its promoter region. The main goal of this study is a comparison of the modulatory effect of LPS treatment on HFV-1 transcription and virus production in a promonocytic cell line and primary monocyte-derived macrophages (MDM). We found that LPS increases virus gene expression in THP89GFP cells by activation of NF-KB, which is in sharp contrast with what is seen in primary MDM even though NF-KB and TNF-a were both stimulated upon treatment of the latter cell type by LPS. More importantly, our findings reveals that conclusions made with established human-derived cell lines cannot be directly applied to the situation prevailing in a more natural cellular setting. Thus, the response to TLR ligands should be studied in an appropriate cell culture System to more closely parallel the in vivo situations.
122

Effet de la stimulation des TLR sur l'infection par le VIH-1 des lymphocytes T CD4+ et des cellules dendritiques primaires

Thibault, Sandra 13 April 2018 (has links)
Depuis sa découverte en 1983, le virus du SIDA ne cesse de faire des ravages. Malgré l’apparition de la thérapie HAART, qui permet de prolonger l’espérance de vie des individus atteints, aucun traitement n’est actuellement disponible pour prévenir ou éradiquer complètement l’infection. Le virus mute beaucoup ce qui lui confère rapidement une résistance à l’ensemble des traitements utilisés. L’objectif actuel du monde scientifique est donc de développer d’autres cibles qui pourraient restreindre les effets indésirables des médicaments actuels tout en diminuant l’émergence de souches virales résistantes. Afin de développer ces nouveaux traitements, il est essentiel de mieux comprendre le comportement du virus et ce, sous diverses conditions de l’organisme. Mon projet de doctorat s’inscrit dans cette thématique puisqu’il a permis d’étudier le comportement du virus suite à la stimulation du TLR2, un récepteur essentiel à la reconnaissance, entre autre, de structures spécifiques des bactéries Gram positives. L’objectif global consistait à déterminer si la stimulation de ce TLR, par un ligand synthétique, avait des effets sur l’état d’activation et le taux d’infection des lymphocytes T CD4+ naïfs et mémoires de même que celui des cellules dendritiques. Les résultats obtenus indiquent que la stimulation du TLR2 augmente l’infection de ces deux types cellulaires et favorise également le transfert du virus des cellules dendritiques aux lymphocytes T CD4+. Sachant que l’activation des cellules favorise l’infection par le VIH 1 et que les produits bactériens présents dans la circulation sanguine lors de la translocation microbienne activent les lymphocytes T CD4+ et les cellules dendritiques, toutes les conditions sont alors réunies pour mener à une hyperactivation des cellules immunes. Ces résultats démontrent que la reconnaissance des produits microbiens par les TLR participe à la dissémination de l’infection en favorisant l’activation de cellules permissives à l’infection. / Since its discovery in 1983, HIV-1 continues to destroy many people lives and no treatment is actually available to treat or prevent infection. Despite the utilization of HAART therapy, the epidemy is still increasing and the worldwide really need new treatments. Due to his high capacity of mutations, HIV-1 rapidly develops resistance against all available treatments. The major aim of scientific community is to develop new therapeutics using different targets to try to avoid and control the resistance phenomenon. To develop these treatments, it is very important to acquire a better understanding of the HIV-1 biology. My doctorate project is tightly related to this because it permits to study the reaction of HIV-1 following TLR2 stimulation, a receptor very useful to sense pathogens. Since microbial translocation is a phenomenon frequently observed in HIV-1-patients, characterized by the presence of bacterial compounds into bloodstream, we evaluated if TLR2 stimulation, with a synthetic ligand, could modulated infection process. Our global objective was to determine if this stimulation could change the activation state and influence the infection in both CD4+ T lymphocytes and dendritic cells. Our results confirmed that TLR2 stimulation increases infection in both cell subtypes and also increases the transfer of viruses from dendritic cells to CD4+ T lymphocytes. Knowing that cell activation favors HIV-1 infection and that bacterial compounds present into bloodstream during microbial translocation stimulate TLR2 stimulation activates CD4+ T cells and dendritic cells, all conditions are put together to favors hyperactivation of the immune system. Our results demonstrate that TLR2 stimulation participates to HIV-1 dissemination by triggering activation of immune cells.
123

Optimisation de l'immunothérapie non spécifique du cancer superficiel de la vessie

Ayari, Cherifa 18 April 2018 (has links)
Le cancer superficiel de la vessie (CSV) présente un taux élevé de récidive (60%). De ces récidives 10 à 15% progresseront vers un cancer infiltrant beaucoup plus dangereux. La résection transurétrale (RTU) des tumeurs superficielles est souvent suivie d’immunothérapie intravésicale par le BCG (Bacille-Calmette-Guérin) afin de prévenir la récidive et la progression ; cependant ce traitement échoue dans 40% des cas. De plus, la sévérité des effets secondaires empêche plusieurs patients de tolérer un traitement complet. La prédiction de la réponse au BCG et le développement de traitements alternatifs s’avèrent donc nécessaires. Nous avons d’abord évalué la signification clinique de la présence de cellules dendritiques matures infiltrant la tumeur (CDIT) et de macrophages associés aux tumeurs (MAT) dans des CSV à bas risque, traités seulement par RTU. La présence de CDIT a permis d’identifier des patients à risque élevé de progression. Chez des patients à haut risque de récidive et de progression traités au BCG, nous avons observé que ceux qui ont un haut niveau d'infiltration par des CDIT ou des MAT ne répondaient pas efficacement au BCG. Dans un deuxième volet, j’ai exploré la possibilité d’utiliser d’autres agents théarapeutiques pouvant se combiner au BCG ou le remplacer pour stimuler la réponse antitumorale. Pour un tel rôle j’ai choisi les agonistes des Toll-like receptors (TLR). Les TLR, principalement exprimés par les cellules du système immunitaire et quelques cellules épithéliales, jouent un rôle important dans l’immunité innée en reconnaissant des motifs moléculaires conservés de pathogènes. J’ai d’abord montré que les TLR sont exprimés et fonctionnels dans des cellules urothéliales normales et tumorales. Par la suite, j’ai démontré que le poly(I :C), agoniste du TLR3, a un effet cytotoxique et antiprolifératif direct sur des lignées de cancer de vessie. Dans les cellules MGH-U3, il induit également la sécrétion de cytokines pro-inflammatoires et induit fortement l’expression des molécules du CMH de classe I alors que le BCG a très peu d’effet sur l’immunogénicité de ces cellules. Un essai d’inhibition de croissance tumorale utilisant le modèle de cancer de vessie murin MBT-2 a montré que l’utilisation combinée du BCG et du poly(I :C) inhibe très significativement la croissance tumorale alors que chacun des produits utilisés seuls n’avait pas d’effet significatif. Notre étude suggère que le poly(I :C) dû à ses effets anti-néoplasiques pourrait améliorer l’efficacité thérapeutique du BCG dans l’immunothérapie du CSV. / Non-muscle invasive bladder cancer (NMIBC) is characterized by a high rate of recurrence (60%). Ten to fiftheen % of the recurrences will progress toward muscle-invasive tumors, which are more dangerous. Transurethral resection (TUR) of non-muscle invasive tumors is frequently followed by intravesical immunotherapy using BCG (bacillus Calmette-Guérin) to prevent recurrence and progression but this treatment fails in 40% of cases. Moreover, the severity of the side effects prevents many patients to comply with the whole treatment. Tools to predict the response to BCG and the development of alternative treatments are therefore required. We first evaluated the clinical significance of the presence of tumor infiltrating mature dendritic cells (TIDCs) and of tumor-associated macrophages (TAMs) in low-risk NMIBCs treated only by TUR. The presence of TIDCs allowed the identification of patients that were at high risk of progression. In patients with NMIBCs at high risk of recurrence and progression treated with BCG, we observed that those with a high level of MAT or TIDC infiltration did not respond efficiently to BCG. In the second part of my work, I have explored the possibility to use other immunomodulatory agents to replace or complement BCG immunotherapy. I therefore selected toll-like receptors (TLRs) agonists for this purpose. TLRs, which are mainly expressed in immune cells but also epithelial cells, play an important role in the innate immunity by recognizing molecular patterns that are conserved between pathogens. I have first showed that TLRs are expressed and functional in normal and tumor urothelial cells. Then, I showed that poly(I:C), a TLR3 agonsist, has direct cytotoxic and antiproliferative effects on bladder cancer cell lines. In MGH-U3 cells, it induces the secretion of proinflammatory cytokines and expression of major histocompatibility class I molecules whereas BCG has little effect on the immunogenicity of these cells. A growth inhibition assay using the MBT-2 murine bladder cancer model showed that the combination of poly(I:C) and BCG inhibited very significantly the growth of bladder cancer cells whereas each product alone had no significant effect. Our study suggests that poly(I:C), due to its anti-tumoral effects, could improve the therapeutic efficacy of BCG for the immunotherapy of NMIBCs.
124

Epigenetic Alterations of Toll-Like Receptors by TET2 in Spontaneous Preterm Labor

Chumble, Anuja 01 January 2014 (has links)
Increasing evidence implicates the presence of bacteria in intrauterine tissues as an important risk factor for spontaneous preterm labor. Epigenetic alterations of innate immunity genes may increase the mother’s sensitivity to subclinical levels of bacteria. This study examined the presence of TET2, TLR-2, and TLR-9 in intrauterine tissue, and evaluated whether epigenetic alterations of these genes, as well as IL-8, changed their expression in human decidual tissue and a macrophage cell culture. Immunohistochemicalstaining was used to detect the presence of these proteins in intrauterine tissue. Gene expression changes were evaluated in stimulated monocytes and macrophages. Fluorescence immunohistochemistry was used to track translocation of TET2 in stimulated monocytes and macrophages. Secreted IL-8 concentration was detected with ELISA. Decidual expression of TET2, TLR-2, and TLR-9 increased in the order TNL < TL < sPTL < iPTL. This study found that TET2, TLR-2, TLR-9, and IL-8 are regulated by epigenetic mechanisms. This study was the first to report activation of TET2 involves its translocation from the cytosol to the nucleus in macrophages.
125

Toll-like receptor 4 (TLR4) na modulação da imunidade do tipo 2. / Toll-like receptor 4 (TLR4) and modulation of Th2 immunity.

Bortolatto, Juliana 16 October 2008 (has links)
Lipopolissacarídeos (LPS), pode tanto proteger quanto exacerbar o desenvolvimento da asma. LPS inicia a ativação da resposta imune via ligação da molécula Toll-like receptor 4 (TLR4) que sinaliza por duas vias distintas, as moléculas adaptadoras MyD88 e TRIF. LPS é um adjuvante que induz resposta do tipo Th1, enquanto que o hidróxido de alumínio (Alum) desperta respostas Th2, porém, a mistura de ambos adjuvantes na indução da resposta alérgica pulmonar ainda não foi investigada. No presente estudo, nós determinamos o efeito de dois agonistas de TLR4, um natural (LPS) e outro sintético (ER-803022) adsorvidos ao Alum sobre o desenvolvimento de doença alérgica pulmonar. Os animais foram sensibilizados pela via subcutânea com os antígenos, Ovoalbumina (OVA) ou Toxóide Tetânico (TT) na presença ou ausência de agonistas de TLR4 co-adsorvidos ao Alum e desafiados com os respectivos antígenos pela via intranasal. Nossos resultados mostraram que a sensibilização com OVA ou TT e LPS coadsorvidos ao Alum, impede o estabelecimento da resposta alérgica mediada por linfócitos Th2, tais como, influxo de eosinófilos, produção de citocinas do tipo 2, hiperreatividade brônquica, secreção de muco, e produção de IgE ou IgG1 anafilática. Apesar dos níveis de IgG2a, isotipo associado com as respostas Th1 estarem aumentados, análise da histopatologia pulmonar não revelou um desvio para o padrão Th1 de inflamação. Verificamos que a presença das moléculas TLR4, MyD88, IL-12/IFN-g mas não TRIF foram necessários para LPS exercer seu efeito inibitório. O agonista sintético de TLR4, menos tóxico que LPS, também protegeu contra o desenvolvimento de inflamação alérgica pulmonar. Em conclusão, nosso trabalho esclarece o efeito da sinalização do TLR4 na sensibilização alérgica e indica que agonista sintético de TLR4 com baixa toxicidade, pode ser utilizado para modular a capacidade adjuvante do Alum e conseqüentemente diminuir a indução de alergias. / Epidemiological and experimental data suggest that bacterial lipopolysaccharides (LPS) can either protect from or exacerbate allergic asthma. LPS triggers immune responses through Toll-like receptor (TLR) 4 that in turn activates two major signaling pathways via either MyD88 or TRIF adaptor proteins. LPS is a pro-Th1 adjuvant while aluminum hydroxide (Alum) is a strong Th2 adjuvant, but the effect of mixing both adjuvants on development of lung allergy has not been investigated. We determined whether natural (LPS) or synthetic (ER-803022) TLR4 agonists adsorbed onto alum adjuvant affect allergen sensitization and development of airway allergic disease. To dissect LPS-induced molecular pathways we used TLR4, MyD88, TRIF, or IL-12/IFN-g deficient mice. Mice were sensitized subcutaneously to allergens such as ovalbumin (OVA) or tetanus toxoid (TT) with or without TLR4 agonists coadsorbed onto Alum and challenged twice via intranasal route with the same allergens. The development of type 2 immunity was evaluated 24 h after last allergen challenge. We found that sensitization with OVA or TT plus LPS co-adsorbed onto Alum impaired allergeninduced Th2-mediated responses such as airway eosinophilia, type 2 cytokines secretion, airway hyperreactivity, mucus hyper production and serum levels of IgE or IgG1 anaphylactic antibodies. Although the levels of IgG2a, a Th1 affiliated isotype increased, investigation into the lung-specific effects revealed that LPS did not induce a Th1 pattern of inflammation. LPS impaired the development of Th2 immunity, signaling via TLR4 and MyD88 molecules via the IL-12/IFN-g axis, but not through TRIF pathway. Moreover, the synthetic TLR4 agonists that proved to have a less systemic inflammatory response than LPS also protected against allergic asthma development. TLR4 agonists co-adsorbed with allergen onto Alum down modulate Th2 immunity and prevent the development of polarized T cell-mediated airway inflammation. Thus, our work clarifies the effect of TLR4 signaling in allergic sensitization and indicates that TLR4 agonists with low toxicity might be useful for down regulating the pro-Th2 adjuvant activity of alum and consequently decrease the induction of allergy.
126

Relação entre o oncogene BCR-ABL e os receptores de tipo TOLL (TLR). / Relationship between the oncogene BCR-ABL and Toll-like receptors (TLR).

Zenteno, María Emilia 17 November 2010 (has links)
Recentemente, a expressão gênica dos receptores TLR foi encontrada em diversos tipos de células tumorais. A sua participação na biologia do câncer é controversa já que foram descritas ações pró e anti-tumorais após a ativação de sua sinalização. Na Leucemia Mielóide Crônica (LMC) nada se tem demonstrado. BCR-ABL é uma oncoproteína quimérica cujo sítio tirosina quinasa constitutivamente ativado promove inúmeras vias de sinalizações que desencadeia a transformação celular. Este trabalho se inicia com a hipótese de existir uma relação entre o oncogene BCR-ABL e a expressão dos receptores TLRs. Nós verificamos em células murinas TonB210.1 com expressão de BCR-ABL induzível por doxiciclina que Tlr1 e Tlr2 tem sua expressão gênica relativa aumentada na presença da oncoproteína. A regulação positiva de Tlr1 é dependente da ação tirosina quinasa de BCR-ABL. Também mostramos que as vias p38 e JNK estão reprimindo a expressão de Tlr1 induzida por BCR-ABL enquanto que a via ERK é utilizada pelo BCR-ABL para promovê-la. Por outro lado, observamos que a ligação de TLR1/TLR2 com seu agonista sintético Pam3CSK4 em células TonB210.1 BCR-ABL positivas induz um aumento da produção de IL-6 e leva ao aumento da resistência a morte quando induzida pelas drogas Ara-C e VP16. Em conclusão, estes resultados indicam que BCR-ABL esta regulando a expressão gênica de alguns TLRs. Por tanto esses dados contribuem para a compreensão sobre o comportamento de células tumorais BCR-ABL positivas em um contexto de infecção e por conseqüência, dão margem ao estudo de novos alvos de fator de risco para a LMC. / Recently, the gene expression of TLR receptors have been described in several kinds of tumour cells. Its participation in cancer biology is controversial because roles were already been described in pro and anti-tumoral activities after their signaling activation. In Chronic Myeloid Leukemia (CML) there are no published data. BCR-ABL is a quimeric protein and its tyrosine-kinase site is activated constitutively. Thus, many signaling pathways are activated and several cell processes are altered thereby resulting in cellular transformation. This work has started with the hypothesis that a putative relationship between the oncogene BCR-ABL and the expression of TLR receptors could exists. We verified in murine cells TonB210.1 BCR-ABL expression inducible by doxycicline that Tlr1 and Tlr2 have their relative gene expression up-regulated in the presence of the oncoprotein. Therefore the Tlr1 regulation is dependent of BCR-ABL tyrosine kinase action. Using MAPK inhibitors we showed that p38 and JNK pathways are suppressing the TLR1 induction by BCR-ABL while ERK pathway is used by the oncoprotein for promote it. On the other hand, we observed in TonB210.1 BCR-ABL positive cells that the binding of TLR1/TLR2 heterodimer to their synthetic agonist Pam3CSK4 induced an increased production of IL-6 and when these cells were induced by Ara-C and VP-16 drugs the apoptosis resistance increased. In conclusion, these results indicate that the oncoprotein regulates the gene expression of some TLRs. Therefore, this fact gives us data about the behavior of BCR-ABL positive tumor cells in the context of infection and in consequence the study of new risk factor targets for CML.
127

Traitement anticancéreux et modulation du système immunitaire / Effects of Anticancer Agents on Immune Responses

Zoubir, Mustapha 06 April 2012 (has links)
Les thérapies anticancéreuses ont apporté un gain largement reconnu en matière de réduction de la charge tumorale, de survie des patients et d’amélioration de leur qualité de vie, dans un certain nombre de cancers. Hélas, ces thérapies exercent un effet immunosuppresseur en détruisant les effecteurs ou en bloquant l’activité de certains facteurs biologiques impliqués dans le recrutement des acteurs du système immunitaire. D’autre part, plusieurs travaux ont permis de démontrer que ces traitements pouvaient avoir un effet contraire en générant ou en favorisant l’induction d’une réponse immunitaire anti-tumorale, soit par effet direct sur le recrutement et l’activation des effecteurs de l’immunité, soit en potentialisant les interactions cellulaires par des mécanismes biologiques. Ces derniers faisant intervenir les cytokines, la stimulation des TLR, l’augmentation des interactions entre cellules du SI; ce qui permet de passer d’une anergie immunologique vers un véritable système d’éradication des cellules cancéreuses.Dans notre laboratoire, nous avons essayé d’évaluer l’implication du système immunitaire dans la réponse thérapeutique induite par des agents cytotoxiques conventionnels. Ici, nous décrivons les effets d’un inhibiteur de cyclines kinases multi-cibles « CDKi PHA-793 887 » testé dans un essai de phase I mené sur deux sites en Europe. C’est le constat inattendu que 6 des 15 patients, traités par ce médicament (PHA-793887) ont développé de graves infections bactériennes et virales et que 6 d’entre eux ont présenté la réactivation du virus de l’herpès qui nous a conduit à étudier ces effets sur le système immunitaire et en particulier sur le dialogue entre cellules dendritiques (CD) et cellules natural killer (NK). Ce travail met en évidence que ce médicament inhibe le signalling des récepteurs toll-like (TLR) réduisant par conséquent l’interaction CD/NK in vitro. Enfin la stimulation des cellules des patients sous traitement démontre une réduction importante de ce signalling ex-vivo. Ainsi, cet effet immunosuppresseur inattendu a permis une réactivation virale chez 40% des patients. La deuxième partie de ce travail, concerne les effets du cyclophosphamide (CTX) utilisé à faible dose. L’injection d'une faible dose chez la souris ou d’un dosage métronomique chez l'homme, promeut la différenciation des cellules lymphocytaires vers Th17 (sécrétant de l’interleukine-17 (IL-17)) et Th1 (sécrétant de l’interféron-γ (IFN)). Ceux-ci ont été retrouvés dans le sang et dans des ascites carcinomateuses de patients. Ainsi, le CTX pourrait participer à la génération de réponses anti-tumorale via la différenciation Th 17 comme cela fut suggéré par de récentes études précliniques montrant l’existence d’une corrélation étroite entre le taux des lymphocytes Th17 infiltrant la tumeur et la destruction tumorale. / Cancer therapies have made a gain widespread recognition in the reduction of tumor burden, patient survival and improved quality of life in a number of cancers. Unfortunately, these therapies exert an immunosuppressive effect by killing effectors or blocking the activity of certain biological factors involved in recruiting of the immune system. On the other hand, several studies have shown that these treatments could have the opposite effect by generating or promoting the induction of antitumor immune response, either by direct effect on the recruitment and activation of effectors immunity, either by potentiating cellular interactions by biological mechanisms. The latter involving cytokines, TLR stimulation, increased interactions between cells of the IS; which toggles between immunological anergy to a real system to eradicate cancer cells. In our laboratory, we tried to evaluate the involvement of the immune system in the therapeutic response induced by conventional cytotoxic agents. Here, we describe the effects of an inhibitor of cyclin kinases multi-target "CDKIs PHA-793887" tested in a phase I trial conducted at two sites in Europe. This unexpected finding is that 6 of 15 patients treated with this drug (PHA-793887) developed severe bacterial and viral infections and six of them showed reactivation of the herpes virus that has led us to study these effects on the immune system and in particular on the dialogue between dendritic (DCs) and natural killer (NK) cells. This work shows that this drug inhibits the signaling of toll-like receptor (TLR) thereby reducing the interaction DC / NK in vitro. Finally, stimulation of the cells of treated patients demonstrated a significant reduction of this signaling ex vivo. Thus, this immunosuppressive effect has an unexpected viral reactivation in 40% of patients. The second part of this work concerns the effects of metronomic dose of cyclophosphamide (CTX). The injection of a low dose in mice or metronomic dosing in humans, markedly promotes the differentiation of CD4+ T helper 17 (Th17) cells that can be recovered in both blood and tumor beds. However, CTX does not convert regulatory T cells into Th17 cells and promotes cell differentiation into Th17 lymphocytes (secreting interleukin-17 (IL-17)) and Th1 (secreting interferon-γ (IFN)). These were found in blood and in ascites carcinoma patients. Thus, CTX may participate in the generation of antitumor responses through Th 17 differentiation as was suggested by recent preclinical studies showing the existence of a correlation between the rate of Th17 lymphocytes infiltrating the tumor and tumor destruction.
128

Vliv proteinu HBx viru hepatitidy B na aktivaci MEK1/2-ERK signalizace a inhibici IFN typu I v hepatocelulární linii Huh7 / Effect of HBV protein HBx on activation of MEK1/2 signaling and inhibition of type I IFN in hepatoma cell line Huh7

Berehovska, Olena January 2019 (has links)
Hepatitis B virus (HBV) infection is one of the major causes of chronic and cancerous liver disease. Elimination of HBV from chronically infected patients by recombinant interferon α (IFNα) monotherapy shows that the mechanisms of the innate immunity play an important role in suppressing viral infection. However, the mechanisms of recognition of the HBV genome and its escape from the mechanisms of natural immunity are still little known. One of the principal factors enabling the virus to escape from cellular restriction mechanisms is the HBx viral protein. HBx is a 154 amino acid pleiotropic multifunctional protein affecting transcription, signal transduction, cell cycle, protein degradation, apoptosis, and chromosomal stability in the host cell. Previous results from our laboratory have shown that activation of the MEK1/2-ERK signaling pathway in plasmacytoid dendritic cells leads to inhibition of IFNα production. The aim of my work was to determine whether HBx activates the MEK1/2-ERK pathway and thus inhibits IFN type I production also in hepatocytes. For this purpose, I monitored HBx production in the Huh7 hepatoma cell line by transfecting the bicistronic plasmid pHBx- IRES-EGFP and Western blotting. Using the same method, I monitored activation of the MEK1/2-ERK signaling pathway by ERK...
129

Toll-like receptor 4 (TLR4) na modulação da imunidade do tipo 2. / Toll-like receptor 4 (TLR4) and modulation of Th2 immunity.

Juliana Bortolatto 16 October 2008 (has links)
Lipopolissacarídeos (LPS), pode tanto proteger quanto exacerbar o desenvolvimento da asma. LPS inicia a ativação da resposta imune via ligação da molécula Toll-like receptor 4 (TLR4) que sinaliza por duas vias distintas, as moléculas adaptadoras MyD88 e TRIF. LPS é um adjuvante que induz resposta do tipo Th1, enquanto que o hidróxido de alumínio (Alum) desperta respostas Th2, porém, a mistura de ambos adjuvantes na indução da resposta alérgica pulmonar ainda não foi investigada. No presente estudo, nós determinamos o efeito de dois agonistas de TLR4, um natural (LPS) e outro sintético (ER-803022) adsorvidos ao Alum sobre o desenvolvimento de doença alérgica pulmonar. Os animais foram sensibilizados pela via subcutânea com os antígenos, Ovoalbumina (OVA) ou Toxóide Tetânico (TT) na presença ou ausência de agonistas de TLR4 co-adsorvidos ao Alum e desafiados com os respectivos antígenos pela via intranasal. Nossos resultados mostraram que a sensibilização com OVA ou TT e LPS coadsorvidos ao Alum, impede o estabelecimento da resposta alérgica mediada por linfócitos Th2, tais como, influxo de eosinófilos, produção de citocinas do tipo 2, hiperreatividade brônquica, secreção de muco, e produção de IgE ou IgG1 anafilática. Apesar dos níveis de IgG2a, isotipo associado com as respostas Th1 estarem aumentados, análise da histopatologia pulmonar não revelou um desvio para o padrão Th1 de inflamação. Verificamos que a presença das moléculas TLR4, MyD88, IL-12/IFN-g mas não TRIF foram necessários para LPS exercer seu efeito inibitório. O agonista sintético de TLR4, menos tóxico que LPS, também protegeu contra o desenvolvimento de inflamação alérgica pulmonar. Em conclusão, nosso trabalho esclarece o efeito da sinalização do TLR4 na sensibilização alérgica e indica que agonista sintético de TLR4 com baixa toxicidade, pode ser utilizado para modular a capacidade adjuvante do Alum e conseqüentemente diminuir a indução de alergias. / Epidemiological and experimental data suggest that bacterial lipopolysaccharides (LPS) can either protect from or exacerbate allergic asthma. LPS triggers immune responses through Toll-like receptor (TLR) 4 that in turn activates two major signaling pathways via either MyD88 or TRIF adaptor proteins. LPS is a pro-Th1 adjuvant while aluminum hydroxide (Alum) is a strong Th2 adjuvant, but the effect of mixing both adjuvants on development of lung allergy has not been investigated. We determined whether natural (LPS) or synthetic (ER-803022) TLR4 agonists adsorbed onto alum adjuvant affect allergen sensitization and development of airway allergic disease. To dissect LPS-induced molecular pathways we used TLR4, MyD88, TRIF, or IL-12/IFN-g deficient mice. Mice were sensitized subcutaneously to allergens such as ovalbumin (OVA) or tetanus toxoid (TT) with or without TLR4 agonists coadsorbed onto Alum and challenged twice via intranasal route with the same allergens. The development of type 2 immunity was evaluated 24 h after last allergen challenge. We found that sensitization with OVA or TT plus LPS co-adsorbed onto Alum impaired allergeninduced Th2-mediated responses such as airway eosinophilia, type 2 cytokines secretion, airway hyperreactivity, mucus hyper production and serum levels of IgE or IgG1 anaphylactic antibodies. Although the levels of IgG2a, a Th1 affiliated isotype increased, investigation into the lung-specific effects revealed that LPS did not induce a Th1 pattern of inflammation. LPS impaired the development of Th2 immunity, signaling via TLR4 and MyD88 molecules via the IL-12/IFN-g axis, but not through TRIF pathway. Moreover, the synthetic TLR4 agonists that proved to have a less systemic inflammatory response than LPS also protected against allergic asthma development. TLR4 agonists co-adsorbed with allergen onto Alum down modulate Th2 immunity and prevent the development of polarized T cell-mediated airway inflammation. Thus, our work clarifies the effect of TLR4 signaling in allergic sensitization and indicates that TLR4 agonists with low toxicity might be useful for down regulating the pro-Th2 adjuvant activity of alum and consequently decrease the induction of allergy.
130

Expressão de genes da resposta imune em bovinos infestados com carrapatos (Boophilus microplus)

Belo, Vanessa de Almeida 15 February 2008 (has links)
Submitted by Renata Lopes (renatasil82@gmail.com) on 2016-10-14T12:30:34Z No. of bitstreams: 1 vanessadealmeidabelo.pdf: 412659 bytes, checksum: 2be0607436379c3a9ca0f2415972f9be (MD5) / Approved for entry into archive by Adriana Oliveira (adriana.oliveira@ufjf.edu.br) on 2016-10-22T13:05:05Z (GMT) No. of bitstreams: 1 vanessadealmeidabelo.pdf: 412659 bytes, checksum: 2be0607436379c3a9ca0f2415972f9be (MD5) / Made available in DSpace on 2016-10-22T13:05:05Z (GMT). No. of bitstreams: 1 vanessadealmeidabelo.pdf: 412659 bytes, checksum: 2be0607436379c3a9ca0f2415972f9be (MD5) Previous issue date: 2008-02-15 / Nos países tropicais, as perdas causadas pela infestação de carrapatos em bovinos acarretam um grande impacto no sistema de produção animal. Recentes estudos têm mostrado a importância de fatores genéticos ligados a resistência a carrapato em Bos taurus indicus e Bos taurus taurus e que as citocinas têm um papel crítico na prevenção ou progressão de doenças. O objetivo desse trabalho foi avaliar os níveis de expressão dos genes IL-10 e IL-4 relacionados ao perfil imunológico Th2 associado à susceptibilidade ao carrapato e os genes IL-2 e IFN- relacionados ao perfil imunológico Th1 associado à resistência ao parasito. Além destes genes, analisou-se o perfil de expressão do gene TLR-2, importante no processo de reconhecimento de patógenos e os genes IL-8 e TNF-α importantes no processo inflamatório inicial. Seis animais mais resistentes e seis animais mais susceptíveis de uma população F2 de 332 animais, originária do cruzamento de animais F1(½ Holandês: ½ Gir), foram selecionados baseado na contagem de carrapatos e valor genético. Amostras de tecido foram coletadas de pele no 5° e 12° dias após a infestação para extração de RNA total. As PCRs em tempo real foram realizadas usando o gene GAPDH como controle endógeno. Os animais resistentes e susceptíveis apresentaram aumento de expressão do gene IL-10 no 5° (p<0,01) e 12 ° dias após a infestação (p<0,05). O gene IL-2, nos animais resistentes e susceptíveis, no 5° dia após a infestação não apresentou alteração da expressão sendo que 12° dia, em ambos os grupos de animais, este gene passou a ser mais expresso em relação ao animal controle sugerindo um perfil de resposta imunológica do tipo de Th2 nos animais resistentes e susceptíveis nos primeiros dias após a infestação. O gene IL-4 apresentou uma tendência ao aumento de expressão nos animais resistentes e susceptíveis em relação ao controle, sendo o perfil Th2 sugerido atribuído a IL-10 produzida por linfócitos T regulatórios (p>0,05). O gene TNF- apresentou aumento de expressão nos animais susceptíveis no 5° dia após a infestação com posterior diminuição no 12° dia após a infestação (p<0,05). Nos animais resistentes não foi observada alteração da expressão deste gene, isto sugere que ele possa estar mais atuante no início do processo inflamatório, logo após a fixação do carrapato. A mesma observação estende-se para o gene IL-8, em que não foi verificada alteração de expressão nos animais resistentes, embora nos animais susceptíveis este gene apresentou diminuição da expressão no 12° dia após a infestação (p<0,05). Quanto ao gene IFN-, não houve diferença de expressão entre os animais resistentes e susceptíveis, sendo que este gene parece não estar relacionado ao mecanismo de resistência. O gene TLR-2 apresentou diminuição da expressão em ambos os grupos de animais. Estes resultados sugerem que a resposta imune adquirida avaliada neste trabalho não apresenta papel preponderante no mecanismo de resistência e que resposta imune inata poderia está envolvida no mecanismo de resistência ao carrapato. Portanto, avaliação da resposta imunológica horas após a fixação do carrapato poderia nos fornecer resultados mais conclusivos. / In tropical countries losses caused by tick infestation in cattle lead to a major impact on animal production systems. Recent studies have shown the importance of genetic factors linked to tick resistance in Bos indicus and Bos taurus as well as the critical role in the prevention or progression of diseases mediated by cytokines. The aim of this work was to evaluate gene expression of IL-10 and IL-4 in relation to tick susceptibility associated with the Th2 profile and gene expression of IL-2 and IFN- in relation to tick resistance associated with the Th1 profile. In addition, the expression of TLR-2, important in the process the recognition of pathogens, and TNF-α and IL-8 genes, important in the initial inflammatory process, were evaluated. Six tick-resistant and six tick-susceptible animals from a F2 population of 332 animals, originated from the cross of F1 animals (½ Holstein: ½ Gir), were selected based on tick count and breeding value for tick resistance. Skin biopsies were collected in the 5th and 12th days after tick infestation. The GAPDH was used as endogenous control to normalize the amount of starting cDNA target in the real-time PCR assay. Both resistant and susceptible animals showed increased gene expression of IL-10 in the 5th and 12th days after infestation in relation to control animal (p<0.05). The IL-2 gene showed no change of expression in the 5th day after infestation for the resistant and susceptible animals. In the 12th post infestation, both resistant and susceptible animals showed increased gene expression in relation to control animal. These results suggest an enhancement of Th2 profile through the increase of IL-10 mRNA levels and a possible inhibition of the Th1 pattern in both groups (resistant and susceptible) starting 5 days after infestation and return to normal by day 12. Despite our results suggest the occurrence of the Th2 profile, the susceptible and resistant animals did not show variation on gene expression for IL-4 in relation to control animal. The susceptible animals showed increased expression of TNF-α in the 5th day after infestation. However, in the 12th day post infestation it was noted a decrease in the gene expression level. The resistant animals showed no change in the expression of this gene in relation to control animals suggesting that TNF-α could be more actively expressed in the early steps of the inflammatory process. Similarly, the resistant animals showed no variation in the expression of IL-8 while the susceptible animals showed increased expression in the 12th day post infestation. There were no differences of expression between resistant and susceptible animals in relation to IFN-γ what suggests that this gene might not be involved in the resistance mechanism. The TLR-2 gene showed decreased expression in both resistant and susceptible animals (p<0.05). Finally, there was no difference in expression between susceptible and resistant animals in relation to all selected genes in the 5th and 12th days after infestation. These results suggest that the acquired immunity evaluated in this work might not have preponderant role in the resistance mechanism. The innate immunity might be playing a major role in the bovine tick resistance/susceptibility mechanism in early hours after infestation.

Page generated in 0.0371 seconds